Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages 580-590

  Koga Yamakawa, Erina ^a   Dovedi, Simon J ^b   Murata, Masashi ^a   Matsui, Hiroyuki ^a   Leishman, Andrew J ^b   Bell, John ^b   Ferguson, Douglas ^b   Heaton, Simon P ^b   Oki, Toshihiro ^a   Tomizawa, Hideyuki ^a   Bahl, Ash ^b   Takaku, Haruo ^a   Wilkinson, Robert W ^b   Harada, Hideyuki ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b ASTRAZENECA   (United Kingdom)

Author keywords

adjuvant therapy; cancer; immune; TLR 7

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12P40; SM 276001; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; B LYMPHOCYTE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CELL ACTIVATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG EFFICACY; KIDNEY CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; MAXIMUM PLASMA CONCENTRATION; METASTASIS; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR VOLUME;

EID: 84870249921     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27691     Document Type: Article

References (37)

1. Girart MV, Fuertes MB, Domaica CI, et al. Engagement of TLR3, TLR7, and NKG2D regulate IFN-{gamma} secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol 2007; 179: 3472-9.
2. Isabelle B-D, Gaetan J,. Toll-like receptors: sentries in the B-cell response. Immunology 2009; 128: 311-23.
3. Hamm S, Rath S, Michel S, et al. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol 2009; 6: 257-65.
4. Dudek AZ, Yunis C, Harrison LI, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007; 13: 7119-25.
5. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-83.
6. Zou W,. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
7. Datta SK, Redecke V, Prilliman KR, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003; 170: 4102-10.
8. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
9. Vandenabeele P, Declercq W, Van Herreweghe F, et al. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 3: re4.
10. Kamath AT, Sheasby CE, Tough DF,. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol 2005; 174: 767-76.
11. Lee J, Chuang TH, Redecke V, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003; 100: 6646-51.
12. Nishiya T, DeFranco AL,. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004; 279: 19008-17.
13. Schon MP, Schon M,. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27: 190-9.
14. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 1259-68.
15. Broomfield SA, van der Most RG, Prosser AC, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009; 182: 5217-24.
16. Rajagopal D, Paturel C, Morel Y, et al. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010; 115: 1949-57.
17. Thyrell L, Hjortsberg L, Arulampalam V, et al. Interferon α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 2004; 279: 24152-62.
18. Kayagaki N, Yamaguchi N, Nakayama M, et al. Type I interferons (IFNs) regulate tumor necrosis factor related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451-60.
19. Smits EL, Ponsaerts P, Berneman ZN, et al. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008; 13: 859-75.
20. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
21. Isobe Y, Kurimoto A, Tobe M, et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem 2006; 49: 2088-95.
22. Vogel SN, English KE, O'Brien AD,. Silica enhancement of murine endotoxin sensitivity. Infect Immun 1982; 38: 681-5.
23. Wang D, Precopio M, Lan T, et al. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther 2010; 9: 1788-97.
24. Hashimoto M, Niwa O, Nitta Y, et al. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 1989; 80: 459-63.
25. Mangsbo SM, Ninalga C, Essand M, et al. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother 2008; 31: 34-42.
26. Reeves DJ, Liu CY,. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009; 64: 11-25.
27. Collaborators MRCRC,. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Medical research council renal cancer collaborators. Lancet 1999; 353: 14-7.
28. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6: 1678-92.
29. Oh JZ, Kurche JS, Burchill MA, et al. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 2011; 118: 3028-38.
30. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
31. Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28: 4324-32.
32. Waitz R, Solomon SB, Petre EN, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2011; 72: 430-9.
33. Dharmapuri S, Aurisicchio L, Neuner P, et al. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther 2009; 16: 462-72.
34. Bergmann JF, de Bruijne J, Hotho DM, et al. Randomized clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011; 34: 443-53.
35. Tran TD, Pryde DC, Jones P, et al. Design and optimization of orally active TLR7 agonists for the treatment of hepatitis C virus infection. Bioorg Med Chem Lett 2011; 21: 2389-93.
36. Xirakia C, Koltsida O, Stavropoulos A, et al. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010; 181: 1207-16.
37. Wang D, Kandimalla E, Yu D, et al. Antitumor activity of a synthetic agonist of TLR9 administered via intranasal route. AACR Meet Abstr 2007; 2007: 3548.